Table 2.

Individual MS Patient Characteristics

Patient	Sex	APOE ε4 Status	MS Phase	MS Onset Age, yr	DMT	PET Imaging Age, yr	MCI	PiB SUVra	AV1451 SUVra
1	F	+	Progressive	29	−	80	−	1.39	−
2	F	−	Relapsing	33	−	77	+	1.23	1.32
3	F	−	Progressive	40	−	75	−	1.33	1.17
4	F	+	Relapsing	46	−	74	−	1.42	−
5	F	−	Relapsing	47	−	69	+	1.38	1.26
6	F	−	Progressive	66	−	67	−	1.35	1.06
7	M	−	Progressive	49	IFNb 1a	64	−	1.42	1.20
8	M	−	Progressive	51	−	63	−	1.38	−
9	M	+	Progressive	53	−	63	+	1.23	1.17
10	F	−	Relapsing	32	−	63	−	1.31	1.27
11	F	−	Relapsing	35	−	58	−	1.55	1.18
12	F	−	Relapsing	52	DMF	57	−	1.40	1.29
13	F	+	Relapsing	43	IFNb 1a	57	−	1.39	1.23
14	M	+	Relapsing	46	IFNb 1a	57	−	1.24	1.16
15	M	−	Relapsing	42	IFNb 1a	53	−	1.33	−
16	F	−	Relapsing	33	−	45	−	1.25	1.14

^aAlzheimer disease signature PiB and AV1451 SUVrs are displayed in the table.

DMF = dimethyl fumarate; DMT = disease‐modifying treatment; F = female; IFNb 1a = interferon beta 1a; M = male; MCI = mild cognitive impairment; MS = multiple sclerosis; PiB = Pittsburgh compound B; SUVr = standardized uptake value ratio.